Ovation Science Inc. (CSE: OVAT)

Summary

Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations as well as other consumer goods made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation’s business model is to develop and market its two product lines ARLO CBD Beauty and Invibe MD, our health and wellness line, as well as continuing to out-license its topical and transdermal formulations to cannabis companies globally. Ovation formulated CBD and THC products are marketed in Nevada in state-approved dispensaries by its US licensee with additional states being added. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales.  Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Stock Chart

Share Structure

As of Feb 28, 2020
Shares Issued 23,203,121
Warrants 4,670,000 @$0.45
OptionsConvertible Notes 1,350,000 @$0.30833,[email protected]$0.30
Fully Diluted 30,056,621

Investment Highlights

  • Market has exponential growth & global prospects
  • Short & long term revenue in progress from ARLO Beauty & US licensee
  • Game changing, high-margin, patented products in high demand
  • Experienced team  of executives, directors & advisors

 

Products

Ovation product 1Ovation product 2Ovation product 3

Management Profiles

Terry Howlett President and Chief Executive Officer, Director

Mr. Howlett founded Skinvisible, Inc. in 1998. With over 35 years of entrepreneurial, business management and market initialization experience, he drives and directs the Company's development and technology vision. He is adept at guiding emerging and publicly traded start-up companies through the stages of capital formation, strategic planning and business growth; specializing in venture capital financing. Mr. Howlett's diversified background includes senior management, marketing, and sales positions with both established and start-up companies, including one of America's premier network marketing companies selling skincare and nutrition products. His skills and strengths in market development, coupled with his impressive range of international contacts in dermatological, medical and financial arenas are cornerstones of Skinvisible's ongoing success.

Logan B. Anderson Chief Financial Officer, Director

Mr. Anderson provides considerable financial and management expertise to Ovation Science Inc. He holds the designation of ACA with the Chartered Accountants (Australia and New Zealand). He began his career as an associate chartered accountant with Coopers & Lybrand in New Zealand and then Canada. This was followed by comptroller of a management services company which was responsible for the management of a number of private and publicly traded companies. Since 1993, Mr. Anderson has served as President of Amteck Financial Services Company, a private financial consulting services company servicing both private and public companies. Mr. Anderson is currently President / Director and on the audit committee of International Battery Metals Inc., President, CEO and Director, of Manado Gold Corp and also as the CFO, Secretary and Director of Wolverine Minerals Inc.

Doreen McMorran Vice President Business Development, Director

Ms. McMorran brings to the Company over 25 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing of dermatology products. Prior to joining Skinvisible in 2008 as Vice President of Business Development, she spent 6 years marketing and selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, and Novartis, as well as providing medical education both traditional and online for physicians and consumers about dermatology conditions, products and treatments. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent 6 years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

James A. Roszell, Ph.D Head of Research & Development

Dr. Roszell is a doctoral chemist with over 40 years experience in product formulation, experimental design, analysis, and method validation. Since joining Skinvisible in 1998, he has been responsible for research and development of the Company's patented technology, related polymer delivery vehicles, product formulations and compositions. Dr. Roszell is a joint contributor to Skinvisible's first patent and responsible for its subsequent patents. Prior to joining Skinvisible, he worked as chemist for Supertech Products, Inc. where his responsibilities included ensuring compliance with OSHA, EPA and other standards and regulations, maintenance of quality control, research and development for new products. His background includes work in chemical, pharmaceutical, environmental and clinical laboratory arenas. His invaluable chemical and scientific expertise is a key factor in Skinvisible's innovative technological achievements now in the cannabis space.

Ian Howard DIRECTOR

Mr. Howard has over 40 years of extensive experience in marketing, government and health care and over 25 years of business experience with Fortune 500 companies internationally including being the former Executive Assistant to two Cabinet Ministers and Senior VP of the National Lottery in Canada. He has worked on most major sporting and public projects in Canada in addition to Europe, Asia and the USA including the 1994 Commonwealth Games, Victoria, 1996 World Conference on AIDS, Vancouver, 1998 Commonwealth Games, Kuala Lumpur, 1998 World Conference on AIDS, Geneva, 2005 World Congress on Melanoma, Vancouver, 2010 Olympic Bid planning and execution. Currently Mr. Howard is the CEO and owner of Leverage Sponsorship Co. and is the COO and Director of SkinCareGuide, an international dermatology medical education company with numerous dermatology publications, websites including Skin Therapy Letter® which is indexed with the National Library of Medicine in Washington.

Joan Chypyha DIRECTOR

Ms. Chypyha has more than 25 years of experience in the pharmaceutical industry holding various senior management positions with an emphasis on marketing, sales and business development, with more than 20 licensing deals and product launches to her credit. In her career, Ms. Chypyha spent 16 years at Hoffmann-La Roche in progressively senior marketing positions; Chief Business-Development Officer at Rhei Pharmaceuticals Ltd.; Vice President of Corporate Development and General Manager of Barrier Therapeutics Canada Inc.; Founder of Alto Pharmaceuticals Ltd, and most recently President and General Manager of Cipher Pharmaceuticals (Canada) (TSE: CPH). Joan earned a BSc from University of Toronto and an Executive MBA from Queen's University.

David Ryan DIRECTOR

Mr. Ryan has extensive experience in investment and public markets. He has been an Investment Advisor for 8 years with a Vancouver, BC firm. For the past 20 years, he has been instrumental in bringing multiple Initial Public Offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings as well as served on the board of public companies in various roles from president to director.